This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Non-Hodgkin lymphoma
  • /
  • Glycoengineered CD20 antibody obinutuzumab activat...
Journal

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.

Read time: 1 mins
Published:14th Nov 2013
Author: Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, et al.
Source: Blood
Availability: Free full text
Ref.:Blood. 2013;122:3482-91.
DOI:10.1182/blood-2013-05-504043
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest